Overview of Vesisol

Quick Facts

Property	Description
Active Ingredient	Solifenacin succinate
Form	Film-coated tablet
Pharmacological Class	Anticholinergic (Muscarinic antagonist)
Common Use	Management of overactive bladder symptoms
Origin	Synthetic compound

What is Vesisol and Its Medicinal Classification?

Vesisol is a prescription-only medicine whose primary active ingredient is Solifenacin. It is classified within the major pharmacological class of anticholinergics, specifically identified as a competitive muscarinic receptor antagonist. Vesisol is a synthetic compound derived from the quinuclidine derivative structure, used as a single-agent monotherapy to modulate involuntary smooth muscle activity. Solifenacin acts on specific receptor subtypes within the body. This confirms that the drug uses a targeted method to influence the bladder's function, an action clinically recognized for managing this type of muscle activity.

Active Ingredient and Pharmaceutical Form of Vesisol

The functional substance is Solifenacin, presented chemically as the salt Solifenacin succinate. Vesisol is an oral preparation administered as a film-coated tablet, differentiating it from liquid or injection forms. The formulation includes the accurately dosed active compound combined with solid pharmaceutical excipients forming the tablet core. Solifenacin is a selective M3 receptor antagonist, meaning it preferentially targets the receptors responsible for bladder contraction. This high degree of selectivity is a key differentiating feature from older, less-selective anticholinergics.

Vesisol’s General Purpose and High-Level Action

The general purpose of Vesisol is to provide control over symptoms associated with the overactive bladder (OAB) state. A typical use scenario involves its application to reduce the high frequency of urination often experienced by adult patients with the condition. Its high-level physiological action involves achieving inhibition of detrusor muscle contraction by providing a targeted blockade of muscarinic receptors. This action permits the bladder muscle to relax, which is essential for managing the involuntary contractions that cause symptoms such as urgency and urinary frequency associated with the condition.

Regulatory References

Solifenacin Drug Information

What side effects are possible with Vesisol?

Possible Side Effects and Safety Information

Vesisol (solifenacin) is associated with side effects that primarily reflect its antimuscarinic mechanism. The most common adverse reactions reported in clinical trials, occurring in a significant percentage of patients, include dry mouth (the most frequent event, which is dose-related) and constipation. Other common effects involve the gastrointestinal and urinary systems, as well as blurred vision and urinary tract infection.

Serious Adverse Reactions and Restrictions

Official safety documentation highlights a risk of serious and potentially life-threatening reactions, including Angioedema of the face, lips, tongue, and/or larynx, and Anaphylactic Reactions. These hypersensitivity events have been reported in postmarketing surveillance and can occur after the first dose. If these symptoms occur, the drug must be discontinued immediately.

Safety restrictions mean Vesisol is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to the drug. Caution is required in patients with clinically significant bladder outlet obstruction or decreased gastrointestinal motility.

Population and Dose Considerations

The maximum recommended daily dose of Vesisol should not exceed 5 mg in patients with severe renal impairment (creatinine clearance < 30 mL/min), moderate hepatic impairment (Child-Pugh B), or when the drug is co-administered with potent CYP3A4 inhibitors (such as ketoconazole), to prevent increased exposure and risk of side effects. Use is generally not recommended in patients with severe hepatic impairment (Child-Pugh C). Additionally, the drug may cause antimuscarinic CNS effects (e.g., somnolence, confusion, or hallucinations), and there is a risk of impaired body temperature regulation, potentially leading to heat stroke.

System-Organ Class	Common Adverse Reactions (from clinical trials)
Gastrointestinal Disorders	Dry mouth, Constipation
Infections and Infestations	Urinary tract infection
Eye Disorders	Blurred vision

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Vesisol (Solifenacin succinate) overdose centers on the potential for severe antimuscarinic effects. The primary risk involves an acute escalation of the drug’s pharmacological action. Documented clinical manifestations of overexposure include signs affecting the Central Nervous System (CNS) and the cardiovascular system, such as mental status changes, a decrease in the level of consciousness, tremors, and mydriasis (fixed and dilated pupils).

Severe systemic risks officially noted may include acute urinary retention, gastrointestinal issues like colonic obstruction, and significant cardiac effects, such as Electrocardiogram (ECG) QT prolongation and Torsades de Pointes.

The regulatory guidance mandates that individuals seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if severe signs, such as collapse, a seizure, or trouble breathing, are observed. Management protocols described in official documentation confirm that no specific antidote is available. Treatment is focused on symptomatic and supportive measures. Officially described procedural steps include the administration of activated charcoal and the performance of gastric lavage. Regulatory documentation explicitly states that vomiting should not be induced as a response to overdose.

Therapeutic Uses of Vesisol

Main Uses of Vesisol

Vesisol is a medication primarily indicated for the treatment of symptoms associated with an overactive bladder. This condition occurs when the bladder muscles contract involuntarily, even when the bladder is not full. The active component in Vesisol belongs to a class of medications known as antimuscarinics or anticholinergics, which work by relaxing the bladder muscles.

The medication is used to manage several specific symptoms:

Urge Incontinence: A sudden, strong need to urinate followed by the involuntary leakage of urine.
Urinary Urgency: An immediate and compelling desire to pass urine that is difficult to delay.
Urinary Frequency: The need to urinate much more often than usual, typically defined as needing to go eight or more times in a 24-hour period.

Therapeutic Benefits

The primary goal of Vesisol therapy is to improve the functional capacity of the bladder and reduce the impact of overactive bladder symptoms on daily life. By inhibiting specific receptors in the bladder wall, the medication helps to increase the volume of urine the bladder can hold and decreases the frequency of muscle spasms.

Key benefits observed during treatment include:

Reduction in Episodes: A decrease in the number of daily accidents or instances of urinary leakage.
Improved Bladder Control: Greater ability to delay urination once the urge is felt, providing more time to reach a bathroom.
Normalization of Voiding Patterns: A reduction in the total number of trips to the bathroom during both the day and night.

By managing these symptoms, the medication aims to help individuals maintain their routine activities with fewer interruptions caused by bladder instability.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Vesisol (Solifenacin succinate) is officially approved for use exclusively in adult patients (aged 18 and over), including the elderly. Safety and effectiveness have not been established in the pediatric population (under 18 years), and its use is therefore not recommended in this age group.

Contraindicated Populations

Use of Vesisol is absolutely forbidden (contraindicated) in patients with the following conditions, as stated in regulatory labels:

Hypersensitivity to the drug or its components.
Urinary retention or gastric retention.
Uncontrolled narrow-angle glaucoma.
Severe hepatic impairment (Child-Pugh Class C).
Myasthenia gravis or a severe gastrointestinal condition like toxic megacolon.

Conditional Use Restrictions

Special caution and official dose restrictions are required for patients with impaired organ function or when taking certain other medications:

Population/Condition	Regulatory Requirement (Max Dose)
Severe Renal Impairment (CrCl le 30 mL/min)	Must not exceed 5 mg once daily
Moderate Hepatic Impairment (Child-Pugh B)	Must not exceed 5 mg once daily
Potent CYP3A4 Inhibitor Use	Must not exceed 5 mg once daily

For pregnancy, Vesisol is classified to be used only if the potential benefit justifies the potential risk. Use during lactation is not recommended.

What should I know about interactions with other medicines?

The interaction profile of Vesisol (Solifenacin succinate) is primarily defined by regulatory classifications concerning pharmacokinetic effects involving the CYP3A4 enzyme and pharmacodynamic effects related to its anticholinergic activity.

Pharmacokinetic Interactions and Restrictions

Vesisol is categorized as a substrate for the metabolic enzyme CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir, Itraconazole) results in a documented increase in systemic exposure, specifically a rise in the Area Under the Curve (AUC). Regulatory documents note that in patients with severe renal impairment or moderate hepatic impairment, co-administration with these strong inhibitors is subject to significant restriction due to this exposure increase.

Pharmacodynamic Interactions

Due to its core anticholinergic properties, Vesisol exhibits documented additive pharmacodynamic effects when used with other anticholinergic medicinal products, which may lead to more pronounced effects. Conversely, the official labeling states that Vesisol can reduce the effect of medicines that stimulate gastrointestinal motility (e.g., Metoclopramide) through antagonism. Furthermore, caution is documented regarding the potential for pathological QT/QTc prolongation when Vesisol is co-administered with drugs already known to affect cardiac conduction, such as Thioridazine or Erythromycin. Regulatory sources specify that an interval of approximately one week should be allowed before commencing other anticholinergic therapy after Vesisol discontinuation. The absorption of Vesisol is documented to have no significant interaction with food and can be taken independently of mealtimes.

Mechanism of Action

Targeted Action on Muscarinic Acetylcholine Receptors

Vesisol's mechanism of action is centered on acting as an antagonist at specific muscarinic acetylcholine receptors ( M3) located on the detrusor muscle. By competitively blocking the binding of the neurotransmitter acetylcholine (ACh) to these receptors, Vesisol interferes with cholinergic signaling necessary for muscle cell depolarization.

Modulation of Detrusor Smooth Muscle Signaling

This targeted receptor blockade modifies the intracellular signal transduction cascade by preventing the downstream events, such as calcium release, necessary for smooth muscle contraction. This activity results in a reduction of signal propagation required for sustained smooth muscle contraction.

Physiological Consequences of Receptor Antagonism

Interference with the contractile signal results in reduced detrusor smooth muscle tone. This physiological consequence is associated with alterations in bladder wall compliance and muscle stretching characteristics during filling.

Dosage and Administration Information

How to Use Vesisol

This section outlines the standardized administration principles for Vesisol (Solifenacin succinate). The medicine is intended for continuous, long-term use and is administered via the oral route as a film-coated tablet.

Standard Dosing Regimens

The established dosage is taken once daily.

Parameter	Instruction (Adults)
Starting Dose	5 mg once daily
Maintenance Dose	5 mg to 10 mg once daily
Maximum Daily Dose	10 mg

The 5 mg starting dose may be adjusted to the maximum dose of 10 mg based on individual response.

Administration Requirements and Restrictions

All Vesisol tablets must be swallowed whole with liquid and should not be crushed, chewed, or divided. The dose may be taken with or without food.

If a dose is missed, it should be taken as soon as it is remembered on the same day, unless it is close to the next scheduled dose; a double dose should not be taken to compensate.

Population-Specific Dose Limits

There are specific dose limits for certain patient groups:

Severe Renal Impairment (CLcr ≤ 30 mL/min):
- Maximum daily dose is restricted to 5 mg.
Moderate Hepatic Impairment (Child-Pugh B):
- Maximum daily dose is restricted to 5 mg.
Co-administration with Potent CYP3A4 Inhibitors:
- Maximum daily dose is restricted to 5 mg.

The safety and efficacy of Vesisol have not been established in patients under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vesisol

Evidence for Use in Overactive Bladder (OAB) in Adults

The primary body of research that has examined Vesisol for Overactive Bladder in adults consists of short-term, randomized, double-blind, placebo-controlled trials. In these trials, adult patients with OAB were studied for outcomes related to physical discomfort and outcomes describing episodic changes, such as urinary frequency and urgency. Researchers monitored patient-reported outcomes relevant in evidence describing how symptoms are measured by using daily diaries.

The studies focused on measuring key functional changes. These included tracking the mean number of voids per 24 hours and the mean number of urge urinary incontinence episodes per 24 hours to observe how symptoms evolved in the observed populations. Findings describe patterns observed in the studies, including measurements taken when compared to an inactive substance (placebo).

The large core studies are assigned a high level of evidence quality, but evidence remains limited regarding the longest-term effects. Results observed in the studies apply only to the populations studied under the specific trial conditions, and there is limited information for long-term outcomes to understand how symptoms may evolve over many years.

Evidence for Use in Neurogenic Detrusor Overactivity (NDO) in Pediatrics

The research base for Vesisol in pediatric patients (children and adolescents) with Neurogenic Detrusor Overactivity (NDO) follows a different design than the adult OAB trials. This research was evaluated in children aged 2 to under 18 years with NDO linked to neurological conditions. In these studies, researchers monitored both clinical and functional endpoints, tracking changes in Maximum Cystometric Capacity (MCC) and bladder compliance, alongside symptom-based outcomes like the daily number of incontinence episodes.

Due to the specific nature of NDO, the sample sizes were modest. The results apply only to the populations studied and for the observation times used (up to one year), which means long-term effects are not fully established by this controlled evidence.

Assessing the Consistency and Strength of Research Evidence

The research for the adult OAB indication consists of multiple large-scale, randomized, controlled trials (RCTs), and is assigned a high evidence level. The findings from these trials were subsequently pooled and analyzed in systematic reviews and meta-analyses, which contribute to the broader evidence landscape. For the NDO indication in pediatrics, the evidence quality varies across studies, but regulatory data assign a moderate to high evidence level. The evidence describes group patterns, not personal outcomes, and research provides context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Vesisol (FAQ)

Q: How long does it typically take for Vesisol to start working?

Studies and official information indicate that the active ingredient, solifenacin, reaches its highest concentration in the bloodstream within about 3 to 8 hours after a dose. However, patients participating in clinical trials usually had their outcomes assessed after 12 weeks of continuous use to determine the full extent of symptom change.

Q: Can taking Vesisol make you feel sleepy or tired?

Official product information notes that Vesisol may cause somnolence, which is the term for sleepiness, as well as other central nervous system (CNS) effects. Dizziness and general feelings of unusual tiredness or weakness have also been reported as side effects in some patients. It is important that patients are aware of how the medicine may affect them.

Q: Can Vesisol be taken with common over-the-counter pain relievers?

Regulatory documents state Vesisol is processed by the CYP3 A4 enzyme and can interact with other medications. Patients are advised to inform their healthcare provider about all other products they take, including over-the-counter medicines and supplements. Official guidance is provided so that a medical professional can review all products for potential interactions.

Q: What happens if Vesisol is taken with supplements like magnesium or vitamin C?

Regulatory documents advise patients to tell their doctor about all supplements, including vitamins and herbal products. Vesisol should be used with caution in people with electrolyte disturbances, such as low levels of magnesium or potassium. These disturbances can be affected by certain types of supplements or laxatives.

Q: Is Vesisol safe for older adults (seniors)?

Vesisol is approved for use in all adult patients, which includes the elderly. Official studies found no overall difference in how well the drug worked or its safety profile between older and younger adults. Dose restrictions are described in the official documents for older patients who have severe kidney or moderate liver impairment.

Q: What does the latest clinical evidence say about Vesisol’s effectiveness?

In clinical studies lasting 12 weeks, the use of Vesisol was found to significantly decrease two key measurements compared to an inactive substance (placebo). These measurements were the mean number of voids (urinations) per 24 hours and the mean number of incontinence episodes (leaks) per 24 hours.

Q: Does Vesisol interact with common blood pressure medicines?

Official documentation does not specifically list common blood pressure medicines as a prohibited interaction. However, caution is noted when Vesisol is taken alongside any drugs known to prolong the QT interval, which relates to the heart's electrical activity. The assessment of all co-administered medications for potential risks is the role of a healthcare professional.

Q: Can Vesisol make me feel dizzy or lightheaded?

Official documentation lists dizziness as a common adverse reaction in clinical trial data for Vesisol. Less commonly, lightheadedness and fainting (called syncope) have also been reported. These are potential central nervous system (CNS) side effects.

Q: Does taking Vesisol require any special monitoring or blood tests?

Official guidelines advise that patients be monitored for potential anticholinergic CNS side effects, especially when starting the drug or changing the dosage. Specific bladder volume monitoring may be recommended for patients with existing bladder outlet obstruction due to a potential risk of urinary retention.

Q: What are the key points patients should know before starting Vesisol?

Key warnings in the official patient information section include risks of serious angioedema (swelling of the face or throat) and potential central nervous system side effects like dizziness and sleepiness. The drug is contraindicated (use is prohibited) in patients who have conditions such as urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.

Q: Can Vesisol affect fertility?

Based on non-clinical data from animal studies, there was no evidence found to suggest an effect on male or female fertility. Regulatory documents, therefore, do not indicate that taking the drug will reduce fertility in humans.

Q: Is Vesisol a controlled substance?

Official government classification confirms that Vesisol (solifenacin succinate) is not listed as a controlled substance and is not scheduled by the Drug Enforcement Administration (DEA). This means it is not associated with being habit-forming or addictive.

Q: How important is it to finish the full course of Vesisol as prescribed?

Official documentation indicates that Vesisol is intended for the continuous, long-term use of overactive bladder symptoms. The effectiveness of the drug is based on continuous use, with clinical trials assessing results over a period of 12 weeks or more.

Q: Are the side effects of Vesisol generally severe?

Most common side effects reported, such as dry mouth and constipation, are generally mild. However, official safety documentation warns of rare but serious risks, including Angioedema (swelling of the face or tongue) and Anaphylactic Reactions. Official documentation states that these serious reactions must result in immediate discontinuation.

Q: Is it normal to feel [mild, common side effect] when starting Vesisol?

The official product information lists dry mouth and constipation as the most common adverse effects observed in clinical trials. As these are the most frequent effects, experiencing them when beginning treatment is consistent with the data seen in studied populations.

Q: What is the purpose of the different strengths Vesisol comes in?

Vesisol is available in two dose strengths. The official guidelines explain that the starting dose may be adjusted to the maximum dose based on how an individual patient responds to the medicine. This flexibility is described in the regulatory prescribing information.

Q: Can Vesisol affect my ability to drive or operate machinery?

Because Vesisol can cause certain central nervous system effects, such as dizziness, somnolence (sleepiness), or blurred vision, the official labeling includes a warning. Due to these risks, patients are advised to exercise caution regarding activities requiring high concentration, such as driving or operating machinery.

Q: Where can I find the official package insert for Vesisol online?

The official product labeling, often referred to as the package insert, can be found on regulatory websites such as the U.S. National Library of Medicine’s DailyMed database or the European Medicines Agency (EMA) website. These sources contain the full prescribing information and patient-specific details.

Q: How quickly does Vesisol leave the body once I stop taking it?

After continuous use, the active ingredient, solifenacin, has a terminal elimination half-life ( t1/2) of approximately 45 to 68 hours. This measurement is used to estimate how long it takes for the concentration of the drug in the body to decrease by half.

Q: Is Vesisol a branded drug, or is a generic available?

Vesisol is the brand name for the medicine. The active ingredient is solifenacin succinate. The generic form of solifenacin succinate is available for this medication.

Q: Are there any contraindications related to Vesisol and heart conditions?

Regulatory documents state that Vesisol is not recommended for patients who are at a high risk of QT prolongation. This is a specific electrical change in the heart, and this risk applies to people with a known history of the condition or those taking medications that affect the heart's electrical rhythm.

Q: What is the difference between the immediate-release and extended-release forms of Vesisol?

Vesisol is officially available as a film-coated tablet designed for oral administration once daily. Official labeling does not mention or distinguish between separate immediate-release or extended-release formulations for Vesisol.

Q: Does Vesisol interact with herbal remedies like St. John's Wort?

Since Vesisol is metabolized by the CYP3 A4 enzyme, its official labeling warns about potential interactions. Herbal remedies, such as St. John's Wort, are known to affect this enzyme. Official sources advise informing a healthcare provider about the use of all herbal products.

How should Vesisol be stored and disposed of?

How to Store and Dispose of Vesisol

Official regulatory documents define strict conditions for the storage and disposal of Vesisol (Solifenacin succinate) tablets to maintain product stability and safety.

Storage Requirements

Vesisol must be stored at controlled room temperature, typically between 15°C to 30°C (59°F to 86°F), and kept from freezing or exposure to excess heat. The medicine must remain in its original container, which should be tightly closed and stored away from moisture and direct light. Storage in the bathroom is prohibited due to humidity concerns.

Child Safety and Disposal

For safety, the medicine must be stored out of the sight and reach of children, with all safety caps securely locked. When the tablets are expired or unused, they must be safely thrown away after consulting a healthcare professional for guidance. Vesisol is not on the list of medicines recommended for disposal by flushing.

Vesisol